Home > Analyse
Actualite financiere : Actualite bourse

Johnson & Johnson: buys oncolytic virus firm BeneVir

(CercleFinance.com) - Johnson & Johnson's Janssen said on Wednesday that it has bought US-based BeneVir Biopharm for an undisclosed amount, in a bid to expand into oncolytic viruses that infect and destroy cancer cells.

The US-based diversified healthcare group said that oncolytic viral immunotherapy holds "exciting potential" in the treatment of solid-tumour cancers (lung, prostate, colorectal, etc.).

The deal is expected to be closed in the second quarter of 2018.

Copyright (c) 2018 CercleFinance.com. All rights reserved.